NEW ORLEANS, LA—Ceftaroline fosamil is associated with high rates of clinical success among patients with gram-positive bacteremia after prior antibiotic treatments, researchers reported at IDWeek 2016.
“Clinical success was demonstrated in patients with gram-positive bacteremia treated with ceftaroline fosamil, including patients infected with MRSA [methicillin-resistant Staphylococcus aureus] or MSSA [methicillin-susceptible S. aureus],” reported lead study author Christy Maggiore, Pharma, BCPS, of the Gulf Coast Medical Center in Panama City, FL.
Most patients were administered ceftaroline fosamil as a second- or later-line therapy, she noted.
CAPTURE was a retrospective, multicenter study that assessed the clinical use of ceftaroline fosamil in the United States. Two hundred and fifty-two study participants with gram-positive bacteremia were administered ceftaroline fosamil.
Risk factors for bacteremia included intravascular device (IVD; 43.7%), followed by hemodialysis (19.0%), prior Staphylcoccus aureus bacteremia (15.9%) and injection drug use (10.7%), Dr. Maggiore reported. MRSA was isolated in 71% of patients; MSSA in 12.3%, and coagulase-negative staphylococci in 9.5%.
Most (90%) of patients had been administered antibiotics prior to ceftaroline fosamil, most commonly vancomycin and piperacillin (67%) with tazobactam (31%). Patients received ceftaroline fosamil for a median of 7 days (range, 2–68 days); three-quarters of patients received a dose every 12 hours.
“Overall clinical success was 77.4%,” Dr. Maggiore reported. “Clinical success in those with an IVD was 77.3% (85/110), previous S. aureus bacteremia was 80.0% (32/40), hemodialysis was 75.0% (36/48), injection drug use was 85.2% (23/27), and previous endocarditis was 83.3% (10/12).”
Among patients with MRSA- or MSSA- bacteremia, clinical success rates were 76.5% and 71.0%, respectively.
“Further clinical studies are warranted to evaluate the use of ceftaroline fosamil in patients with gram-positive bacteremia,” Dr. Maggiore concluded.